Although our findings clearly demonstrate the therapeutic potential of pharmacologically promoting heterotrimer secretion to reduce COL4A1-related ICH and myopathy, they also highlight important limitations when considering the translational potential of this approach. The gene discussed is COL4A1; the disease is myopathy.